Resumen del estudio

Twenty-seven healthy participants were included in this placebo‐controlled, double‐blind, cross‐over study which aimed to characterize the pharmacokinetics and exposure–subjective response relationship of a novel oral solution of lysergic acid diethylamide (LSD). Participants were assigned to complete four experimental 12‐hour test sessions (100 μg LSD, 125 mg methylenedioxymethamphetamine [MDMA], 40 mg D‐amphetamine and placebo) with a washout period of at least 7 days between sessions. Only LSD and placebo data are presented in this study. LSD, O‐H‐LSD, nor‐LSD and iso‐LSD blood plasma concentrations were analysed by ultra‐high‐performance liquid chromatography tandem mass spectrometry and subjective drug effects were measured on a visual analogue scale. First‐order elimination kinetics were observed for LSD. The subjective effects of LSD were closely associated with changes in plasma concentrations over time.